NuroTone Medical

Company Overview

Snapshot

Founded in September 2018 by Yossi Bornstein, Danny Albeck, and Prof. Claus Richter, NuroTone Medical operates with 1–10 employees. The company holds a patent for its technology.

Business overview

NuroTone Medical is a Health Tech & Life Sciences company focused on developing an optical cochlear implant. Its core technology utilizes precise laser stimulation of cochlear neurons to overcome the limitations of existing cochlear implant products, aiming to improve speech recognition, music perception, and reduce sensitivity to environmental noise. The company operates in the Medical Devices sector, serving global markets and targeting healthcare providers and patients with its assistive devices.

Company Intelligence Q&A

What is NuroTone Medical's primary focus?

NuroTone Medical is developing an optical cochlear implant designed to improve hearing capabilities through precise light stimulation of cochlear neurons.

When was NuroTone Medical founded?

NuroTone Medical was founded in September 2018.

Who are the founders of NuroTone Medical?

The company was founded by Yossi Bornstein, Danny Albeck, and Prof. Claus Richter.

What problem does NuroTone Medical aim to solve?

NuroTone Medical aims to overcome the inherent limitations of existing cochlear implant technology by improving speech recognition, music perception, and reducing sensitivity to environmental noise for users.

In which sector does NuroTone Medical operate?

NuroTone Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Assistive Devices.